234 related articles for article (PubMed ID: 30735911)
1. Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway.
Zhou Y; Zhou Y; Yang M; Wang K; Liu Y; Zhang M; Yang Y; Jin C; Wang R; Hu R
Redox Biol; 2019 Apr; 22():101131. PubMed ID: 30735911
[TBL] [Abstract][Full Text] [Related]
2. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
3. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
4. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Palam LR; Gore J; Craven KE; Wilson JL; Korc M
Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
[TBL] [Abstract][Full Text] [Related]
5. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
[TBL] [Abstract][Full Text] [Related]
6. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway.
Gao AM; Ke ZP; Wang JN; Yang JY; Chen SY; Chen H
Carcinogenesis; 2013 Aug; 34(8):1806-14. PubMed ID: 23563091
[TBL] [Abstract][Full Text] [Related]
7. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Cui J; Guo Y; Wu H; Xiong J; Peng T
Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
[TBL] [Abstract][Full Text] [Related]
8. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
9. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Qiu F; Chen J; Cao J; Diao F; Huang P
Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
[TBL] [Abstract][Full Text] [Related]
10. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
11. Periplocin exerts antitumor activity by regulating Nrf2-mediated signaling pathway in gemcitabine-resistant pancreatic cancer cells.
Bae ES; Byun WS; Ock CW; Kim WK; Park HJ; Lee SK
Biomed Pharmacother; 2023 Jan; 157():114039. PubMed ID: 36423542
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract][Full Text] [Related]
13. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
14. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
15. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
[TBL] [Abstract][Full Text] [Related]
16. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Factor Erythroid 2-Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression.
Matsumoto R; Hamada S; Tanaka Y; Taguchi K; Yamamoto M; Masamune A
J Pharmacol Exp Ther; 2021 Oct; 379(1):33-40. PubMed ID: 34321315
[TBL] [Abstract][Full Text] [Related]
18. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
19. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
[TBL] [Abstract][Full Text] [Related]
20. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
